Pemigatinib (FGFR2 Inhibitor)
Treatment for Gallbladder And Biliary Tract Cancer
Typical Dosage: 13.5 mg orally once daily for 14 consecutive days followed by 7 days off
Effectiveness
50%
Safety Score
40%
Clinical Trials
30
Participants
500
Comparative Safety Scale(Higher is safer)
Cyanideâ ī¸
Methđ
CigarettesđŦ
Chemoâĸī¸
Alcoholđē
Morphineđ
Antibioticsđ
Tylenolđ
Exerciseđ
Waterđ§
40
DangerousModerateSafe
Treatment Details
Dosage Range
13.5 mg orally once daily for 14 consecutive days followed by 7 days off
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity (6-18+ months)
Evidence Quality
MODERATEConfidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$225,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$400,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$625,000
Cost per Remission
$7,500,000
Comparison vs Second-line chemotherapy
Cost Difference
+$180,000/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Pemigatinib (FGFR2 Inhibitor) Outcomes
for Gallbladder And Biliary Tract Cancer
Efficacy Outcomes
Overall Effectiveness
+50%
Response Rate
+36%
Remission Rate
+3%
Common Side Effects
Hyperphosphatemia
+70%
Alopecia
+45%
Diarrhea
+35%
Fatigue
+35%
Nail toxicity
+25%
Active Clinical Trials
1 active trial recruiting for Pemigatinib (FGFR2 Inhibitor) in Gallbladder And Biliary Tract Cancer
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
NCT07780838RECRUITINGPHASE2
29 participants
INTERVENTIONAL
Columbus, United States
Started: Nov 1, 2026